Homepage Top Section2

As per the terms of the exclusive worldwide agreement, Agios will acquire the rights to develop and market Alnylam’s preclinical candidate that targets TMPRSS6, a key driver of

The company received the patent from the European Patent Office. The drug is being assessed in the ongoing Phase III programme CONCLUDE for treating patients with moderate to

Co-led by Santé Ventures and Longwood, the financing round has seen participation from Alexandria Venture Investments, Astellas Venture Management, and DCVC Bio. Solu Therapeutics’ CyTaC platform has been

The drug-device combination product, Breyna is claimed to be the first US Food and Drug Administration (FDA)-approved generic version of AstraZeneca’s Symbicort. It will be immediately available in

RiVive is designed to provide access to naloxone without a prescription and is available as 3 mg naloxone hydrochloride nasal spray. This is the second over-the-counter product with

The start-up facilitates analytical and process development, CMC consulting as well as early-stage GMP manufacturing of cell therapies. Initially, its emphasis will be on manufacturing immune cell therapies, such

To be spread over a 69,000ft2 area, the expanded production unit will feature innovative technologies and equipment that aid in developing, producing and analysing advanced therapy medicinal products (ATMP). The

Overland ADCT BioPharma is a joint venture between Overland Pharmaceuticals and ADC Therapeutics. This therapy is seeking an indication to treat adults with relapsed or refractory (r/r) diffuse

The therapy is intended for adults and adolescents aged 12 years and above. This recommendation will be forwarded to the European Commission (EC), which will make a final